---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031348"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:31:31.734388+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Lixte Biotechnology promotes Forman to COO with $200k salary, grants options at $2.00 and warrants at $0.50

## Summary
- Promoted Eric Forman from CAO to VP and COO; salary increased from $175k to $200k.
- Granted options to purchase 200k shares each to Kovach, Forman, Miser, and Weingarten at $2.00/share; market price $0.5025.
- Amended bylaws to reduce stockholder meeting quorum from majority to 33-1/3% of voting power.
- Issued warrants to BioPharmaWorks LLC for 100k shares at $0.5025/share, fully vested, 5-year term.

## SEC filing metadata
- accession: 0001493152-22-031348
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315222031348/0001493152-22-031348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315222031348/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031348
- JSON: https://secwatch.observer/filing/0001493152-22-031348.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031348.txt

## Key facts
- Executive change
  Eric Forman changed role as Vice President and Chief Operating Officer at LIXTE BIOTECHNOLOGY HOLDINGS, INC..
  - Action: promoted
  - Role: Vice President and Chief Operating Officer
  source text: Promoted Eric Forman, the Company’s Chief Administrative Officer, to Vice President and Chief Operating Officer, and increased his annual salary from $175,000 to $200,000 per year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315222031348/0001493152-22-031348-index.htm
- Governance Changes
  LIXTE BIOTECHNOLOGY HOLDINGS, INC.: Reduced the quorum for stockholder meetings from a majority to 33-1/3% of voting power (effective 2022-11-06).
  - Change: bylaw amendment
  - Effective: 2022-11-06
  source text: On November 6, 2022, the Board of Directors of the Company approved Amended and Restated Bylaws. The amendment to the Bylaws was solely in respect to Section 2.8 to reduce the quorum for the transaction of business and all meetings of the stockholders from the holders of a majority to 33-1/3% of the voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315222031348/0001493152-22-031348-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.